Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal groups A, C, Y, W tetanus toxoid conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **quadrivalent conjugate vaccine** designed to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W. Each capsular polysaccharide antigen is chemically conjugated to **tetanus toxoid** protein, enhancing immunogenicity via T-cell dependent pathways. This results in robust, long-lasting antibody and cellular responses (IgG, IgM, IgA) against all four targeted meningococcal groups. MenACWY-TT is administered by intramuscular injection as a single-dose immunization; a booster may be recommended for individuals at continuing risk. It is developed for use in children, adults, and travelers, and is suitable for coadministration with other vaccines. Clinical trials have demonstrated noninferior and sometimes superior immunogenicity compared to older quadrivalent meningococcal vaccines[1][2][3].
- Brand names
- MenQuadfiNimenrix
- Other names
- meningococcal quadrivalent tetanus toxoid conjugate vaccinequadrivalent meningococcal conjugate vaccine (MenACWY-TT)
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal groups A, C, Y, W tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal groups A, C, Y, W tetanus toxoid conjugate vaccine.